

# Ulrike Leiter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6232951/publications.pdf>

Version: 2024-02-01

127  
papers

7,513  
citations

57758

44  
h-index

62596

80  
g-index

150  
all docs

150  
docs citations

150  
times ranked

7757  
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of Melanoma and Nonmelanoma Skin Cancer – The Role of Sunlight. <i>Advances in Experimental Medicine and Biology</i> , 2008, 624, 89-103.	1.6	582
2	Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 757-767.	10.7	562
3	Melanoma epidemiology and trends. <i>Clinics in Dermatology</i> , 2009, 27, 3-9.	1.6	556
4	Epidemiology of Skin Cancer. , 2014, 810, 120-140.		406
5	The natural course of cutaneous melanoma. <i>Journal of Surgical Oncology</i> , 2004, 86, 172-178.	1.7	215
6	Age and gender are significant independent predictors of survival in primary cutaneous melanoma. <i>Cancer</i> , 2008, 112, 1795-1804.	4.1	211
7	Epidemiology of Skin Cancer: Update 2019. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1268, 123-139.	1.6	184
8	Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. <i>Journal of Clinical Oncology</i> , 2019, 37, 3000-3008.	1.6	155
9	Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1860-1867.	0.7	149
10	Determinants of survival in patients with brain metastases from cutaneous melanoma. <i>British Journal of Cancer</i> , 2010, 102, 1213-1218.	6.4	147
11	Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. <i>Archives of Dermatological Research</i> , 2000, 292, 225-232.	1.9	136
12	Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. <i>British Journal of Cancer</i> , 2012, 107, 422-428.	6.4	129
13	Targeting hyperactivation of the <sc>AKT</sc> survival pathway to overcome therapy resistance of melanoma brain metastases. <i>Cancer Medicine</i> , 2013, 2, 76-85.	2.8	126
14	Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2309-2315.	0.7	124
15	Malignant Melanoma S3-Guideline – Diagnosis, Therapy and Follow-up of Melanoma – JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-116.	0.8	122
16	The incidence and mortality of cutaneous melanoma in southern Germany. <i>Cancer</i> , 2006, 107, 1331-1339.	4.1	119
17	Diagnostic value and prognostic significance of protein S100 <sup>β</sup> , melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. <i>Cancer</i> , 2003, 97, 1737-1745.	4.1	115
18	Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. <i>British Journal of Cancer</i> , 2001, 84, 72-79.	6.4	114

#	ARTICLE	IF	CITATIONS
19	Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Journal of Clinical Oncology</i> , 2004, 22, 3660-3667.	1.6	112
20	Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 9001-9007.	1.6	111
21	Mycophenolate mofetil: A new therapeutic option in the treatment of blistering autoimmune diseases. <i>Journal of the American Academy of Dermatology</i> , 1999, 40, 957-960.	1.2	99
22	Is head and neck melanoma a distinct entity? A clinical registry-based comparative study in 5702 patients with melanoma. <i>British Journal of Dermatology</i> , 2006, 155, 771-777.	1.5	98
23	Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns—Results of a non-interventional study of the DeCOG. <i>European Journal of Cancer</i> , 2018, 96, 34-43.	2.8	97
24	Development of prognostic factors and survival in cutaneous melanoma over 25 years. <i>Cancer</i> , 2005, 103, 616-624.	4.1	93
25	Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer. <i>European Journal of Cancer</i> , 2001, 37, 251-259.	2.8	84
26	Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 37-45.	1.2	84
27	Incisional biopsy and melanoma prognosis: Facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 316-318.	1.6	83
28	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. <i>British Journal of Cancer</i> , 2018, 119, 339-346.	6.4	83
29	Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. <i>British Journal of Dermatology</i> , 2018, 178, 443-451.	1.5	78
30	S3 guideline “Diagnosis, therapy and follow-up of melanoma” short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 563-602.	0.8	63
31	S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. <i>Anticancer Research</i> , 2001, 21, 1311-6.	1.1	62
32	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma “ short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 275-294.	0.8	57
33	Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy. <i>PLoS ONE</i> , 2013, 8, e81624.	2.5	54
34	Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry. <i>Journal of Clinical Oncology</i> , 2004, 22, 4376-4383.	1.6	52
35	Open label randomized study comparing 3&eurof months vs. 6&eurof months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 48-53.	2.4	52
36	Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 487-493.	4.2	51

#	ARTICLE	IF	CITATIONS
37	Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. <i>Melanoma Research</i> , 2009, 19, 50-57.	1.2	50
38	Time trends in incidence and mortality of cutaneous melanoma in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1272-1280.	2.4	49
39	Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943â€“2036. <i>European Journal of Cancer</i> , 2021, 152, 18-25.	2.8	49
40	Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976â€“2001. <i>Cancer</i> , 2007, 109, 1174-1182.	4.1	47
41	Treatment of Pemphigus Vulgaris and Bullous Pemphigoid With Mycophenolate Mofetil Monotherapy. <i>Archives of Dermatology</i> , 1999, 135, 724-725.	1.4	46
42	Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. <i>Melanoma Research</i> , 2010, 20, 240-246.	1.2	46
43	Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement. <i>Annals of Surgical Oncology</i> , 2010, 17, 129-137.	1.5	45
44	Current diagnosis and treatment of basal cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 863-875.	0.8	45
45	443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. <i>European Journal of Cancer</i> , 2015, 51, 861-868.	2.8	45
46	The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 248-252.	1.2	44
47	Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. <i>European Journal of Cancer</i> , 2020, 138, 125-132.	2.8	44
48	Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2002, 18, 183-190.	1.5	42
49	Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 517-532.	5.7	41
50	Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. <i>Melanoma Research</i> , 2014, 24, 512-516.	1.2	40
51	Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. , 2020, 8, e000897.		40
52	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020, 38, 2543-2551.	1.6	40
53	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) â€“ short version, part 2: epidemiology, surgical and systemic treatment of cSCC, followâ€“up, prevention and occupational disease. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 400-413.	0.8	39
54	Clinical course and prognostic factors of Merkel cell carcinoma of the skin. <i>British Journal of Dermatology</i> , 2009, 161, 90-94.	1.5	36

#	ARTICLE	IF	CITATIONS
55	Sex differences in survival of cutaneous melanoma are age dependent. <i>Melanoma Research</i> , 2011, 21, 244-252.	1.2	36
56	Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 44-51.	2.4	34
57	Proliferative Activity, Chromosomal Aberrations, and Tumor-Specific Mutations in the Differential Diagnosis between Blue Nevi and Melanoma. <i>American Journal of Pathology</i> , 2013, 182, 640-645.	3.8	33
58	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	1.6	33
59	Chronic cutaneous scleroderoid graft-versus-host disease: evaluation by 20-MHz sonography. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2003, 17, 402-407.	2.4	32
60	Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden, Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 134-142.	2.4	30
61	Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. <i>Melanoma Research</i> , 2011, 21, 228-234.	1.2	29
62	Recurrent nodules in a periauricular plaque-type blue nevus with fatal outcome. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 1088-1093.	1.3	29
63	Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival. <i>Annals of Surgical Oncology</i> , 2015, 22, 4073-4080.	1.5	28
64	Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). <i>Annals of Oncology</i> , 2008, 19, 801-806.	1.2	27
65	Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis. <i>PLoS ONE</i> , 2013, 8, e63137.	2.5	26
66	Pediatric patients with cutaneous melanoma: A European study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26974.	1.5	26
67	Expression of c-myc and bcl-2 in Primary and Advanced Cutaneous Melanoma. <i>Cancer Investigation</i> , 2002, 20, 914-921.	1.3	25
68	The time course of phototoxicity of topical PUVA: 8-methoxypsoralen cream-PUVA vs. 8-methoxypsoralen gel-PUVA. <i>British Journal of Dermatology</i> , 1999, 140, 988-990.	1.5	24
69	Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2570-2577.	0.7	24
70	Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis. <i>JAMA Dermatology</i> , 2021, 157, 1066.	4.1	24
71	Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 311-315.	1.6	23
72	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9300.	4.1	23

#	ARTICLE	IF	CITATIONS
73	Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour. <i>PLoS ONE</i> , 2013, 8, e66953.	2.5	22
74	The evolving field of Dermatologic Oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV and UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	2.4	22
75	Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma. <i>PLoS ONE</i> , 2011, 6, e16882.	2.5	22
76	Melanoma staging: Facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 275-280.	1.6	21
77	Melanoma burden by melanoma stage: Assessment through a disease transition model. <i>European Journal of Cancer</i> , 2016, 53, 33-41.	2.8	20
78	Extramammary Paget's Disease: Extended Subclinical Growth Detected Using Three-Dimensional Histology in Routine Paraffin Procedure and Course of the Disease. <i>Dermatologic Surgery</i> , 2011, 37, 1417-1426.	0.8	19
79	Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 863-868.	1.2	18
80	BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy. <i>PLoS ONE</i> , 2014, 9, e89218.	2.5	18
81	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. <i>Cancers</i> , 2021, 13, 3359.	3.7	18
82	Lymph node dissection for melanoma using tumescence local anaesthesia: an observational study. <i>European Journal of Dermatology</i> , 2018, 28, 177-185.	0.6	17
83	Primary Resistance to PD-1-Based Immunotherapy: A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , 2020, 12, 1027.	3.7	17
84	Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3313-3322.	4.2	17
85	Numerical abnormalities of the Cyclin D1 gene locus on chromosome 11q13 in non-melanoma skin cancer. <i>Cancer Letters</i> , 2005, 219, 197-204.	7.2	16
86	Comparative analysis of incidence and clinical features of cutaneous malignant melanoma in Crete (Greece) and southern Germany (central Baden-Württemberg). <i>British Journal of Dermatology</i> , 2006, 154, 1123-1127.	1.5	16
87	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1075-1082.	4.2	16
88	Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). <i>Klinische Padiatrie</i> , 2017, 229, 322-328.	0.6	16
89	Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2021-2025.	2.4	16
90	Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. <i>European Journal of Cancer</i> , 2019, 123, 83-91.	2.8	15

#	ARTICLE	IF	CITATIONS
91	Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma. PLoS ONE, 2012, 7, e29791.	2.5	14
92	Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. Targeted Oncology, 2021, 16, 197-205.	3.6	12
93	Lack of survival benefit in sentinel lymph nodeâ€‘positive melanoma with immediate complete lymphadenectomy â€‘ a review. JDDG - Journal of the German Society of Dermatology, 2019, 17, 7-13.	0.8	11
94	A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials. Journal of Clinical Medicine, 2020, 9, 2253.	2.4	11
95	Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. Journal of Clinical Medicine, 2020, 9, 1438.	2.4	11
96	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel nodeâ€‘positive melanoma without the need for completion lymph node dissection. European Journal of Cancer, 2020, 134, 9-18.	2.8	11
97	Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. European Journal of Cancer, 2021, 159, 98-104.	2.8	11
98	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers, 2021, 13, 6141.	3.7	11
99	Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases. BioMed Research International, 2013, 2013, 1-5.	1.9	10
100	Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy. European Journal of Cancer, 2016, 67, 38-45.	2.8	10
101	Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under realâ€‘world conditions in Germany â€‘ The nonâ€‘interventional study NIELS. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1678-1685.	2.4	10
102	Treatment of Psoriasis With Calcipotriene Plus Psoralen-UV-A-Bath Therapy. Archives of Dermatology, 1999, 135, 861-862.	1.4	10
103	Clinical determinants of long-term survival in metastatic uveal melanoma. Cancer Immunology, Immunotherapy, 2022, 71, 1467-1477.	4.2	10
104	Malignes Melanom S3-Leitlinie â€‘ Diagnostik, Therapie und Nachsorge des Melanomsâ€‘. JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-126.	0.8	9
105	Quantitation of Herpes simplex DNA in Blood during Aciclovir Therapy with Competitive PCR ELISA. Dermatology, 2000, 201, 296-299.	2.1	8
106	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. Journal of the American Academy of Dermatology, 2019, 80, 1299-1307.e7.	1.2	8
107	S1â€‘guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). JDDG - Journal of the German Society of Dermatology, 2022, 20, 235-243.	0.8	8
108	Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. JDDG - Journal of the German Society of Dermatology, 2019, 17, 999-1004.	0.8	7

#	ARTICLE	IF	CITATIONS
109	Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. <i>European Journal of Cancer</i> , 2022, 166, 60-72.	2.8	7
110	Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity. <i>Cancers</i> , 2022, 14, 518.	3.7	6
111	UVB-induced Decrease of p16/CDKN2A Expression in Skin Cancer Patients. <i>Pigment Cell &amp; Melanoma Research</i> , 2001, 14, 201-205.	3.6	5
112	Management of primary and metastasized melanoma in Germany in the time period 1976â€“2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Melanoma Research</i> , 2008, 18, 112-119.	1.2	4
113	Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 703-708.	2.5	4
114	Late recurrence of melanoma after 10 years â€“ Is the course of the disease different from early recurrences?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 977-983.	2.4	4
115	What causes the death of patients with cutaneous squamous cell carcinoma? A prospective analysis in 1400 patients. <i>European Journal of Cancer</i> , 2022, 172, 182-190.	2.8	4
116	PUVA-bath photochemotherapy for congenital palmoplantar keratoderma in an 11-year-old girl. <i>British Journal of Dermatology</i> , 2000, 143, 464-465.	1.5	3
117	Online consensus conferences for the development and update of clinical practice guidelines: A survey among participants of the German S3 guideline on actinic keratosis and cutaneous squamous cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 608-610.	0.8	3
118	Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany. <i>Acta Dermato-Venereologica</i> , 2021, 102, adv00637.	1.3	3
119	In Reply: Sentinel Lymph Node Biopsy in Melanoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 598-599.	1.5	2
120	Local recurrence and survival in acral lentiginous melanoma comparing 3D histology and conventional histology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 881-889.	0.8	2
121	Follow-up in patients with low-risk cutaneous melanoma: is it worth it?. <i>Melanoma Management</i> , 2014, 1, 115-125.	0.5	2
122	Skin cancer in organ transplant recipients. <i>Expert Review of Dermatology</i> , 2012, 7, 37-45.	0.3	1
123	Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment. <i>International Journal of Dermatology</i> , 2015, 54, 419-423.	1.0	0
124	Kein Ãœberlebensvorteil beim Sentinel-Lymphknoten-positiven Melanom mit sofortiger kompletter Lymphadenektomie â€“ eine Ãœbersicht. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 7-14.	0.8	0
125	Immun-Checkpoint-Blockade bei fortgeschrittenem kutanen Plattenepithelkarzinom: Was wissen wir derzeit im Jahr 2020?. <i>Karger Kompass Dermatologie</i> , 2021, 9, 114-128.	0.0	0
126	What is new in the 2020 British guidelines for cutaneous squamous cell carcinoma?. <i>British Journal of Dermatology</i> , 2021, 184, 384-385.	1.5	0



#	ARTICLE	IF	CITATIONS
127	Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS. Acta Dermato-Venereologica, 2022, , .	1.3	0